儿童炎症性肠病临床试验设计:PIBDnet 评论
本评论由全球儿童炎症性肠病网络(PIBDnet)组织撰写组,经写作组多轮修订与一次面对面会议后,所有声明达成预先设定的>80%共识,并由核心成员投票再次达成>80%共识。全文纳入18条声明,指导从成人数据外推、受试者入选标准、安慰剂使用、给药剂量、终点指标及可行试验建议,并标注了争议问题。
要点
- PIBDnet 发布18条声明指导儿童炎症性肠病临床试验设计。
- 声明覆盖成人数据外推、入选标准、安慰剂、剂量与终点。
- 所有声明经写作组及核心成员投票达成>80%共识。
核心结论
- 本文观点可协助规划兼具高质量与伦理、同时保持务实的儿童炎症性肠病临床试验。
研究设计与样本
- PIBDnet 设立写作组并分配主题,经写作组多轮修订及一次面对面会议后所有声明达成预先设定的>80%共识,随后核心成员投票再次达成>80%共识。
主要发现
- 评论共纳入18条声明,用于指导从成人数据外推、儿童炎症性肠病试验入选标准、安慰剂使用、给药剂量、终点指标及可行试验的建议。
- 文中对存在争议的问题作了重点标注。
关键数值与推荐
- 评论纳入18条声明,涵盖成人数据外推、入选标准、安慰剂、剂量、终点及可行试验建议;所有声明共识度均>80%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The optimal trial design for assessing novel therapies in paediatric IBD (PIBD) is a subject of intense ongoing global discussions and debate among the different stakeholders. However, there is a consensus that the current situation in which most medications used in children with IBD are prescribed as off-label without sufficient paediatric data is unacceptable. Shortening the time lag between adult and paediatric approval of drugs is of the upmost importance. In this position paper we aimed to provide guidance from the global clinical research network (Pediatric Inflammatory Bowel Disease Network, PIBDnet) for designing clinical trials in PIBD in order to facilitate drug approval for children. METHODS: A writing group has been established by PIBDnet and topics were assigned to different members. After an iterative process of revisions among the writing group and one face-to-face meeting, all statements have reached consensus of >80% as defined a priori. Next, all core members of PIBDnet voted on the statements, reaching consensus of >80% on all statements. Comments from the members were incorporated in the text. RESULTS: The commentary includes 18 statements for guiding data extrapolation from adults, eligibility criteria to PIBD trials, use of placebo, dosing, endpoints and recommendations for feasible trials. Controversial issues have been highlighted in the text. CONCLUSION: The viewpoints expressed in this paper could assist planning clinical trials in PIBD which are both of high quality and ethical, while remaining pragmatic.
引用
- Turner D, Griffiths AM, Wilson D, et al. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2019. PMID: 30979718. doi:10.1136/gutjnl-2018-317987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。